Previous 10 | Next 10 |
Data shows patients surveyed had low decision regret 1 after testing with DecisionDx ® -UM, regardless of whether their uveal melanoma tumor was at high or low risk of metastasis Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat...
New data from pooled analysis shows DecisionDx ® -Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk ( T1, ≤1mm) by traditional staging systems Survey of 400 dermatologic clinicians demonstra...
Oregon Health & Science University (OHSU) launched the War on Melanoma to eliminate melanoma as a cause of death Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new collaboration with...
Study shows that DecisionDx®-Melanoma results can provide patients with knowledge and understanding regarding their prognosis and inform melanoma treatment decisions Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the...
This is the second consecutive year that Castle has been recognized for its innovative solutions in dermatology Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company’s DecisionDx®-Melanoma test to risk-stratify patients with cutaneous melanoma accor...
New study data presented at Digestive Disease Week (DDW) 2022 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new study data demonstrating the ability of its TissueCypher® Barrett ...
Research to Prevent Blindness and Castle Biosciences are partnering to provide new opportunities for medical students to pursue ocular cancer research Research to Prevent Blindness (RPB) and Castle Biosciences today announced that they are partnering to increase opportunitie...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients with cutaneous squamous cell carcinoma (SCC) and one or more risk factors a...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...